To truly appreciate the advances offered by GCEA, there's nothing as illustrative as getting in there and running the numbers yourself. However, building a de-novo cost-effectiveness model can be a daunting task. 

Well, not to worry! Just in time for the ISPOR Annual Meeting 2025, we've released an easy-to-use GCEA calculator that allows you to explore and appreciate the societal value of innovative medicines, and underpin the key value drivers without building a full-on model. The GCEA calculator offers an interactive user interface that lets you customize your own GCEA. 

The bottom line is that when it comes to global revenues for innovative medicines, US revenues for “winners” (the top selling drugs) matter most, since these come at the highest profit margin and launch more quickly, and serve as the primary incentive for biomedical innovation.

Generalized cost-effectiveness analysis (GCEA), a framework to comprehensively assess the societal value of innovative health technologies, will be officially debuted at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) conference in Atlanta this week

European central planners should stop trying to talk the US out of incentivizing the development of better medicines that then also help Europeans and the rest of the world. It’s one thing to argue that any one country can’t afford to pay more for new drugs. It’s another thing entirely to put new drugs in jeopardy for everybody by exporting that thinking to the one country whose market-based system has underpinned the last several decades of pharmaceutical advances.